![]() | |
Clinical data | |
---|---|
Routes of administration | Oral, Rectal |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C20H25NO |
Molar mass | 295.426 g·mol−1 |
3D model (JSmol) | |
| |
|
Methoxphenidine (methoxydiphenidine, 2-MeO-Diphenidine, MXP) is a dissociative of the diarylethylamine class that has been sold online as a designer drug.[1][2] Methoxphenidine was first reported in a 1989 patent where it was tested as a treatment for neurotoxic injury.[3] Shortly after the 2013 UK ban on arylcyclohexylamines methoxphenidine and the related compound diphenidine became available on the gray market, where it has been encountered as a powder and in tablet form.[4] Though diphenidine possesses higher affinity for the NMDA receptor, anecdotal reports suggest methoxphenidine has greater oral potency.[1] Of the three isomeric anisyl-substituents methoxphenidine has affinity for the NMDA receptor that is higher than 4-MeO-Diphenidine but lower than 3-MeO-Diphenidine,[3][5] a structure–activity relationship shared by the arylcyclohexylamines.[6]
Acute methoxphenidine intoxication has been reported to produce confusion, hypertension, and tachycardia that was responsive to treatment with intravenous lorazepam,[7][8] methoxphenidine has also been associated with three published fatalities[9] and one case of impaired driving.[10]
Psychotic episodes have also been reported, including a murder in June 2014.[11]
As of October 2015 MXP is a controlled substance in China.[12]
MXP is also banned in Sweden.[13]
In Canada, MT-45 and its analogues were made Schedule I controlled substances, which includes DPD in its structural group.[14] Possession without legal authority can result in maximum seven years imprisonment. Further, Health Canada amended the Food and Drug Regulations in May, 2016 to classify explicitly DPD as a restricted drug. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the drug.
AMPARTooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor |
|
---|---|
KARTooltip Kainate receptor |
|
NMDARTooltip N-Methyl-D-aspartate receptor |
|